Plain-English translation of NCT07513389 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether some patients with HPV-positive throat cancer can safely skip radiation therapy after having robotic surgery to remove the tumor. Instead of getting radiation (the standard treatment after surgery), eligible patients will be closely monitored with blood tests that look for circulating tumor HPV DNA—a marker that can show if cancer cells are still present. If the blood test is negative two weeks after surgery, patients continue surveillance with regular clinical visits and repeat blood tests rather than undergoing radiation.
Radiation after throat surgery can cause significant side effects like difficulty swallowing, dry mouth, and changes to taste and voice. This trial aims to determine whether patients with low-risk features and no signs of remaining cancer in their blood can safely avoid radiation while being carefully watched for any signs of recurrence.
You likely qualify if…
You likely don't qualify if…
You will undergo robotic surgery (TORS) to remove your throat tumor performed by a surgeon experienced in this technique. Two weeks after surgery, you'll have a blood test to check for circulating tumor HPV DNA; if this test is negative, you will not receive radiation therapy. Instead, you'll be followed closely with routine clinical visits and repeat blood tests using a special test called NavDx that looks for signs of cancer DNA, allowing doctors to catch any recurrence early and provide prompt treatment if needed. This intensive monitoring continues throughout your participation in the study.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States